Phase IIa Clinical Trial Results of the Company’s Intranasal COVID-19 Immunotherapy AD17002 Published in the International Journal Human Vaccines & Immunotherapeutics.

December 11, 2024

Phase IIa Clinical Trial Results of the Company’s Intranasal COVID-19 Immunotherapy AD17002 Published in the International Journal Human Vaccines & Immunotherapeutics.

Published data demonstrating that AD17002 exhibits a favorable safety and tolerability profile in patients with mild-to-moderate COVID-19, accelerating viral clearance and shortening the disease course.

‍

Social Share

Company

Introduction

Team & Board of Directors

Partners

Investors

Latest News

R&D Pipeline

Overview

Intranasal Vaccines

Asthma Immunotherapy

Respiratory Antiviral Immunotherapy

Company

R&D Pipeline

Phase IIa Clinical Trial Results of the Company’s Intranasal COVID-19 Immunotherapy AD17002 Published in the International Journal Human Vaccines & Immunotherapeutics.

Company

Introduction

Team & Board of Directors

Partners

Investors

Latest News

R&D Pipeline

Overview

Intranasal Vaccines

Asthma Immunotherapy

Respiratory Antiviral Immunotherapy

Company

R&D Pipeline

Phase IIa Clinical Trial Results of the Company’s Intranasal COVID-19 Immunotherapy AD17002 Published in the International Journal Human Vaccines & Immunotherapeutics.

Advagene's New Drug Demonstrates Potential Against SARS-CoV-2: 《Journal of Microbiology, Immunology and Infection》Publication Highlights Mucosal Immunity and Lung Protection

The Phase II clinical trial of new drug, AD17002, for the treatment of moderate-to-severe asthma has completed the enrollment of all 127 subjects.

The Company Announces First Subject Enrolled in Phase II Clinical Trial of Investigational New Drug AD17002 for Moderate-to-Severe Eosinophilic Asthma.